(MedPage Today) -- A novel agent for treating acute heart failure met one of its two primary endpoints in reducing dyspnea, but which one has not yet been divulged, according to a statement from drug maker Novartis. via MedPageToday.com - medical news plus CME for physicians Read More Here..
For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com
No comments:
Post a Comment